[Anesthesia and hepatic porphyria].

Ann Fr Anesth Reanim

Département d'Anesthésie-Réanimation, Hôpital Laënnec, CHU, Nantes.

Published: July 1989

Three of the acute hepatic porphyrias, acute intermittent porphyria, variegata porphyria and hereditary coproporphyria, are characterized by an idiosyncratic reaction to many common drugs; the resulting excessive excretion of porphyrin precursors is responsible for episodes of acute neurological dysfunction. This review aimed to focus the attention of the anaesthesiologist on the porphyrinogenic properties of all the drugs used in anaesthesia and intensive care. An outline of the chemistry of porphyrins and the enzymatic pathways were recalled, so as to place the acute porphyrias in their proper perspective. There follows a reminder of the clinical aspect of acute porphyric crises. The part played by drugs is then assessed from clinical and laboratory data concerning their porphyrinogenicity. Those drugs for which there is conflicting evidence regarding their safe use in porphyric patients are discussed: propofol, ketamine, benzodiazepines, etomidate, local anaesthetics. Recommendations supported by clinical and experimental data are given, especially the results obtained with the chick embryo liver model. Treatment of the acute crisis is provided, with particular emphasis on the use of haematin. The anaesthetic management of hepatic porphyric patients is described. Those drugs which are well-known porphyrinogenic compounds in the chick embryo liver must be excluded from use for anaesthesia in the porphyric patients, even if they have been observed to be innocuous in rare cases of asymptomatic patients. Finally, recommendations for anaesthesia in symptomatic cutanea porphyria are given.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0750-7658(89)80162-5DOI Listing

Publication Analysis

Top Keywords

porphyric patients
12
chick embryo
8
embryo liver
8
acute
6
drugs
5
[anesthesia hepatic
4
hepatic porphyria]
4
porphyria] three
4
three acute
4
acute hepatic
4

Similar Publications

Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.

Eur Rev Med Pharmacol Sci

April 2024

Department of Biomedical, Metabolic and Neural Science, Neurology Unit, Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.

Background: We describe the first case of a pediatric patient with acute intermittent porphyria and severe chronic porphyric neuropathy treated with givosiran, a small-interfering RNA that drastically decreases delta-aminolevulinic acid production and reduces porphyric attacks' recurrence.

Case Report: A 12-year-old male patient with refractory acute intermittent porphyria and severe porphyric neuropathy was followed prospectively for 12 months after givosiran initiation (subcutaneous, 2.5 mg/kg monthly).

View Article and Find Full Text PDF

Acute encephalopathy (AE) can be a manifestation of an acute porphyric attack. Clinical data were studied in 32 patients during AE with or without polyneuropathy (PNP) together with 12 subjects with PNP but no AE, and 17 with dysautonomia solely. Brain neuroimaging was done in 20 attacks during AE, and PEPT2 polymorphisms were studied in 56 subjects, 24 with AE.

View Article and Find Full Text PDF

Unlabelled: The porphyrias are rare inherited diseases of heme biosynthesis which can involve the nervous system. The most common neurological manifestations of acute intermittent porphyria are autonomic visceral neuropathy, peripheral motor neuropathy, and central nervous system dysfunction. In rare cases, patients with acute intermittent porphyria have presented with cerebral infarction, suggested to be due to vasospasm in cerebral arteries.

View Article and Find Full Text PDF
Article Synopsis
  • Pseudoporphyria (PP) is a rare skin condition that mimics porphyria cutanea tarda but doesn't show porphyrin abnormalities, often affecting patients on dialysis.
  • This condition is characterized by blistering skin lesions that appear in areas exposed to light, and while treatments have been ineffective, N-acetylcysteine has shown mixed results.
  • In a case study, a patient developed severe skin lesions after starting hemodialysis, but these lesions completely healed within 22 days following a kidney transplant, indicating that renal transplantation is a potential cure for dialysis-induced pseudoporphyria.
View Article and Find Full Text PDF

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias.

Front Pharmacol

September 2022

Department of Internal Medicine, Section on Gastroenterology and Hepatology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.

Eslicarbazepine acetate, a third-generation antiepileptic drug (AED), has shown improved clinical response and safety in comparison to older generation AEDs for patients with partial-onset seizures. It is currently not known whether eslicarbazepine acetate is safe to use in patients with the acute hepatic porphyrias (AHPs) since a few first-generation AEDs, such as phenobarbital and carbamazepine, are known porphyrogenic agents. In this study, we used a recently published fluorescence-based screening assay to screen for porphyrogenicity in various agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!